Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 3/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15179340 | 1.00 | ADAM17 (0.46) | ADAM17NQO1MMP2MMP9ACHE | |
| SCHEMBL15179277 | 0.84 | GPR55 (0.57) | ADAM17MMP2MMP9GPR55POLB | |
| SCHEMBL19686989 | 0.84 | GPR55 (0.57) | ADAM17MMP2MMP9GPR55POLB | |
| SCHEMBL18620901 | 0.82 | ADAM17 (0.46) | ADAM17NQO1MMP2MMP9ACHE | |
| SCHEMBL20267139 | 0.75 | ADAM17 (0.44) | ADAM17MMP2MMP9ACHEBCHE | |
| SCHEMBL20267142 | 0.75 | ADAM17 (0.44) | ADAM17MMP2MMP9ACHEBCHE | |
| SCHEMBL4282429 | 0.72 | MCL1 (0.49) | ADAM17NQO1ACHEBCHEMCL1 | |
| SCHEMBL20267141 | 0.71 | ADAM17 (0.41) | ADAM17NQO1MMP2MMP9ACHE | |
| SCHEMBL29182640 | 0.69 | MAOB (0.66) | KMT2A | |
| SCHEMBL28724998 | 0.69 | KDM4E (0.60) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349638-A1 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | TP53, TP53BP1, VHL | ADAM17 226/4885NQO1 2353/4885MMP2 3750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.